Could this sleep drug help Alzheimer's patients rest better?

NCT ID NCT05924425

Recruiting now Symptom relief Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether daridorexant, a sleep medication, can improve sleep in people with mild cognitive impairment or mild-to-moderate Alzheimer's disease who also have insomnia. Sixty-two participants will receive either the drug or a placebo for one month, and their sleep will be measured in a sleep lab. The goal is to see if the drug increases total sleep time and reduces nighttime awakenings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daridorexant
What this could lead to: If it works, this could offer a new sleep medication option for people with Alzheimer's who also have insomnia.
What could go wrong: This is a small, early-phase trial with only 62 participants, so results may not apply to everyone. The drug may not improve sleep significantly or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease insomnia sleep disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE INSOMNIA DISORDER SLEEP

Contacts and locations

Locations

University Hospital, Montpellier
RECRUITING

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.